https://stemcellsjournals.onlinelibrary.wiley.com/doi/10.1002/sctm.19-0037
First‐in‐Human High‐Cumulative‐Dose Stem Cell Therapy in Idiopathic Pulmonary Fibrosis With Rapid Lung Function Decline
The results of this first‐in‐human clinical trial revealed that high cumulative dose of mesenchymal stem cells (MSCs) is safe and well tolerated by patients' idiopathic pulmonary fibrosis with a rapid lung function decline. During the treatment period, the patients in the main group had their lung function increased, as compared to the placebo group, in which the continued decline of the lung function was observed. Thus, this study states the safety, tolerability, and potential benefits of greater doses of MSCs than those used earlier in patients with idiopathic pulmonary fibrosis, and these findings might move future trials toward a new step in stem cells transplantation.
First‐in‐Human High‐Cumulative‐Dose Stem Cell Therapy in Idiopathic Pulmonary Fibrosis With Rapid Lung Function Decline
The results of this first‐in‐human clinical trial revealed that high cumulative dose of mesenchymal stem cells (MSCs) is safe and well tolerated by patients' idiopathic pulmonary fibrosis with a rapid lung function decline. During the treatment period, the patients in the main group had their lung function increased, as compared to the placebo group, in which the continued decline of the lung function was observed. Thus, this study states the safety, tolerability, and potential benefits of greater doses of MSCs than those used earlier in patients with idiopathic pulmonary fibrosis, and these findings might move future trials toward a new step in stem cells transplantation.